Abstract:e15073 Background: BRAF encodes a RAF kinase, which signal downstream of RAS and activate the MAPK pathway, and has emerged as a major oncogenic driver and a potential therapy target. BRAF V600E base substitution is an approved target for the BRAF inhibitors in solid tumors. BRAF gene fusions represent a different mechanism of BRAF activation. BRAF fusions have shown responses to MEK inhibitors and non-specific RAF inhibitors (eg, sorafenib) in Melanoma (NCCN). We sought to analysis of BRAF fusions characteristics in Chinese solid tumor patients to explore the possibility of therapeutic intervention in solid tumors. Methods: We comprehensively characterized BRAF fusions from next-generation sequencing (NGS) data from May 2019 to January 2023 in 80083 various solid tumors. Considering the characteristics of the receptor tyrosine kinase, we focused on the BRAF fusions which contain the kinase domain. Results: A total of 164 unique cases (70.1% (115/164) glioma and 29.9% (49/164) non-glioma with BRAF fusions) were identified. The non-glioma cohort consisted up mainly lung tumors (49%, 24/49), colorectal tumors (18.4%, 9/49), pancreatic tumors (10.2%,5/49), melanoma (9.2%, 4/49) and biliary tumors (4.1%, 2/49). In the glioma cohort, the median age of the 115 patients was 12 with a range of 0–66; 43 (37.4%) of the patients were female and 72 (62.6%) were male. On the other hand, the median age was 64 with a range of 33–82; 23 (46.9%) of the patients were female and 26 (53.10%) were male in the non-glioma cohort. In the glioma cohort, 82.4% of the partners were KIAA1549. However, the most common fusion partners were AGK (14.04%), TRIM24(14.0%), SND1(12.28%), TPK1(8.77%) in the non-glioma cohort. These BRAF fusions comprised 49 unique 5′ fusion partners, of which 51% (25) were known and 49.0% (24) were novel. 14 novel partners were TMEM176B, HMBOX1, SEMA3E, LOC441204, PDE4D, DENND2A, STIM1, TNS3, PRRC2B, BCR, MET, COL4A3BP, TPM4, ZBTB16 and 10 novel partners were intergenic region. 130 patients with BRAF fusions could be evaluated for concurrent mutations. Of interest is that no KRAS and BRAF V600E mutations were identified in the 130 cases. Conclusions: BRAF fusions were detected in 0.2% (164/80083) of Chinese solid tumor patients. 70.1% of BRAF fusion positive cases were diagnosed with glioma and 29.9% were diagnosed with non-glioma. 14 novel BRAF fusion partners were discovered. BRAF fusion is an important driver genomic alteration and occur in a mutually exclusive pattern with other activating mutations in the MAP kinase signaling pathway. BRAF fusion targeted therapies should be further explored in solid tumors.

BRAF mutation in Chinese melanoma patients

Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-Case Cohort.

Analysis of BRAF Gene Mutation of Melanoma Derived from Different Sources

Identification Of Frequent Braf Copy Number Gain And Alterations Of Raf Genes In Chinese Prostate Cancer

Clinical Significance of BRAFV600E Mutation in Circulating Tumor DNA in Chinese Patients with Melanoma

Mutations in Braf Codons 594 and 596 Predict Good Prognosis in Melanoma

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma

Mutational Profiling of Melanomas in Patients from the Southeast Coast of China.

Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Progress on the treatment of BRAF-mutated melanoma

Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases

P1.02-056 BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

The analysis of BRAF fusions characteristics in Chinese solid tumor patients.

Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma.

Clinicopathologic Features and Treatment Efficacy of Chinese Patients with BRAF -Mutated Metastatic Colorectal Cancer: a Retrospective Observational Study

Analysis of Ckit and BRAF Mutations in 43 Chinese Patients with Ocular Melanomas